S&P 500 5,235.18 +1.02%EUR/USD 1.0840 +0.21%GBP/USD 1.2710 +0.14%USD/JPY 149.50 −0.18%BRENT $82.40 −0.81%BTC $67,800 −0.21%GOLD $2,341 +0.55%NASDAQ 16,420.55 +0.74%S&P 500 5,235.18 +1.02%EUR/USD 1.0840 +0.21%GBP/USD 1.2710 +0.14%USD/JPY 149.50 −0.18%BRENT $82.40 −0.81%BTC $67,800 −0.21%GOLD $2,341 +0.55%NASDAQ 16,420.55 +0.74%
A daily business newspaper · Founded in 2026

Money Talk

Finance and markets: business, quotes, gold, energy and releases.

Swiss regulator halts Zurich Insurance policy sales over pricing errors

Swiss financial watchdog FINMA has launched enforcement proceedings against Zurich Insurance Group following disclosures that the company sold corporate life and pension policies at prices inconsistent with regulatory agreements. The regulator has responded by imposing a temporary sales ban on these specific insurance products within the Swiss market.

Swiss regulator halts Zurich Insurance policy sales over pricing errors
Photo: Business Person

The investigation centers on discrepancies between the premiums charged to domestic customers and the pricing structures previously approved by the authorities. Under the current restrictions, the insurer’s corporate life and pensions unit is prohibited from onboarding new clients, limiting its operations exclusively to servicing existing policyholders. While FINMA maintains a policy of not commenting on specific ongoing investigations, it confirmed that it systematically probes potential violations of financial market laws.

Zurich Insurance CEO Mario Greco stated that the sales ban would not affect the group's overall financial performance. Despite this assessment, the company has begun internal restructuring, resulting in the termination of more than 12 employees linked to the units under scrutiny. The duration of the regulatory proceedings remains undisclosed, leaving the firm in a state of operational limbo as it addresses the pricing non-compliance.

Share article
TelegramXFacebook

When reusing this material a link to Money Talk is required.

Comments (0)

Leave a comment

No comments yet. Be the first!